Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 5/20 | 0.41 |
| ▸ | TYMP | P19971 | 5/20 | 0.40 |
| ▸ | TK2 | O00142 | 2/20 | 0.40 |
| ▸ | TK1 | P04183 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211912 | 0.92 | TYMP (0.40) | TOP2ATYMPTK2TK1ALDH1A1 | |
| SCHEMBL19227589 | 0.91 | TYMP (0.48) | TYMPTK2TK1ALDH1A1LMNA | |
| SCHEMBL12286955 | 0.91 | TYMP (0.48) | TYMPTK2TK1ALDH1A1LMNA | |
| SCHEMBL13379950 | 0.91 | TK1 (0.42) | TOP2ATYMPTK2TK1ALDH1A1 | |
| SCHEMBL4405133 | 0.91 | TYMP (0.48) | TYMPTK2TK1ALDH1A1LMNA | |
| SCHEMBL19227501 | 0.88 | TOP2A (0.39) | TOP2ATYMPTK2TK1ALDH1A1 | |
| SCHEMBL19224141 | 0.88 | TOP2A (0.39) | TOP2ATYMPTK2TK1ALDH1A1 | |
| SCHEMBL24264089 | 0.87 | TYMP (0.44) | TYMPTK2TK1ALDH1A1LMNA | |
| SCHEMBL23906513 | 0.85 | TOP2A (0.52) | TOP2ATYMPTK2ALDH1A1LMNA | |
| SCHEMBL14902968 | 0.84 | ALDH1A1 (0.39) | TOP2ATYMPTK2TK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2447274-B1 | Oligomeric compounds and methods | IONIS PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9738895-B2 | Oligomeric compounds and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150167006-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8987435-B2 | Oligomeric compounds and methods | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130156845-A1 | LIPID FORMULATED SINGLE STRANDED RNA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2447274-A2 | Oligomeric compounds and methods | Isis Pharmaceuticals, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110313019-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313019-A1 | OLIGOMERIC COMPOUNDS AND METHODS | HNRNPH1, RNASEH1, HNRNPH3 | TOP2A 2996/4885TYMP 1888/4885TK2 2184/4885 |
| US-20130156845-A1 | LIPID FORMULATED SINGLE STRANDED RNA | RNASEH1, RNASE1, HNRNPH1 | TOP2A 1948/4885TYMP 774/4885TK2 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.